Related Experiment Videos
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501,
K Schreiber1, A B Otura, L P Ryder
1Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Denmark.
Abstract:
As the understanding of the autoimmune inflammatory response in multiple sclerosis (MS) expands, polymorphic genes involved in this process become possible candidates that may determine the severity of disease. Therefore, three candidate genes DRB1*1501, CCR5 and apolipoprotein E (APOE) were examined in a population-based patient sample (n = 70) to assess an association between disease progression measured by clinical disability and MRI parameters. The total lesion area (TLA) on T2-weighted images was measured with a semi-automated threshold technique. Patients with the CCR5delta32 allele showed a non-significant trend towards a smaller lesion burden (TLA/years duration), but were not associated to a milder EDSS/years duration. Our data support previous assumptions of a modulation of severity in MS by the CCR5delta32 genotype, which may convey less inflammation and tissue destruction. Carriers of the DRB1*1501 and APOE-epsilon4 allels did not reveal more severe disease progression, neither by the EDSS/years of duration nor by the TLA/years duration. This study was performed on a population-based sample in a genetically homogeneous Danish population but, due to the limited number of patients examined, weak associations between candidate genes and disease variables cannot be excluded.
Insights
The CCR5delta32 gene variant may reduce inflammation and tissue damage in multiple sclerosis (MS), potentially indicating milder disease progression. However, DRB1*1501 and APOE-epsilon4 showed no significant association with MS severity in this study.
Area of Science:
- Neuroimmunology
- Genetics of Multiple Sclerosis
- Autoimmune Disease Research
Background:
- Understanding the genetic factors influencing multiple sclerosis (MS) severity is crucial for predicting disease progression.
- Polymorphic genes involved in the autoimmune inflammatory response are key candidates for modulating MS outcomes.
Purpose of the Study:
- To investigate the association between specific genetic variations (DRB1*1501, CCR5, and apolipoprotein E (APOE)) and disease severity in multiple sclerosis (MS).
- To assess the relationship between these candidate genes and clinical disability (EDSS) and MRI-derived lesion burden (TLA) in MS patients.
Main Methods:
- Genotyping of DRB1*1501, CCR5 (including CCR5delta32 allele), and APOE (including APOE-epsilon4 allele) in a Danish population-based sample of 70 MS patients.
- Quantification of total lesion area (TLA) on T2-weighted MRI using a semi-automated threshold technique.
- Correlation analysis of genetic data with disease progression metrics: Expanded Disability Status Scale (EDSS)/years of duration and TLA/years duration.
Main Results:
- Patients with the CCR5delta32 allele exhibited a non-significant trend towards a smaller lesion burden (TLA/years duration), suggesting potentially less inflammation.
- No significant association was found between the CCR5delta32 allele and milder clinical disability (EDSS/years duration).
- Carriers of DRB1*1501 and APOE-epsilon4 alleles did not demonstrate a more severe disease progression based on EDSS or TLA metrics.
Conclusions:
- The CCR5delta32 genotype may modulate MS severity, potentially by reducing inflammation and tissue destruction, although this was not significantly linked to clinical disability in this cohort.
- The DRB1*1501 and APOE-epsilon4 alleles were not associated with increased disease severity in this study population.
- Further research with larger sample sizes is warranted to definitively rule out weak associations between these candidate genes and MS disease variables, especially in genetically homogeneous populations.